496 Poster

Altered expression of heat shock protein 110 (HSP110), hypoxia up-regulated 1 (HYOU1) and translationally controled tumor protein (TCTP) during colorectal cancer progression

O. Slaby[1], K. Sobkova[1], M. Svoboda[2], I. Garajova[2], P. Fabian[1], M. Sachlova[2], T. Smerdova[1], D. Knoflickova[1], R. Vyzula[2]
[1]Masaryk Memorial Cancer Institute, Dept. of Oncological and Experimental Pathology, Brno, Czech Republic; [2] Masaryk Memorial Cancer Institute, Dept. of Comprehensive Cancer Care, Brno, Czech Republic

Prognosis of the colorectal cancer (CRC) patients depends on the extend of disease and possibility of curative surgical intervention which is feasible only for patients with disease limited on primary tumor and regional lymph nodes. Spread of the cancer to the lymph nodes is crutial factor for progression and therapeutic management of the disease. We suppose, that analysis of gene expression profiles of CRC patiens by low-density cancer-focused oligonucleotide arrays enable us to identify a new predictive markers of the extend of disease and lead to better understanding of CRC progression. Forty patients who had histologically confirmed colon adenocarcinoma with a volume fraction showing at least 70% of malignant tumor cells were included. Only patients with no prior chemotherapy or radiotherapy were eligible for the study. Total RNA was extracted from each frozen tumor and paired non-tumoral adjacent mucosa stored in RNAlater immediately after surgical resection. Relative expression levels of 440 genes known to be involved in cancer biology were obtained by low-density oligonucleotide microarrays from 22 samples (11 cases of IUCC stage II, 11 cases of IUCC stage III) with the highest RIN (RNA integrity number). Analysis of gene expression data based on SAM (Significance Analysis of Microarrays) and t-test methods identified 3 genes (HSP110, HYOU1, TCTP) significantly up-regulated in primary tumors of patients who developed lymph nodes metastasis. HSP110 and HYOU1 are molecular chaperones and play role in adaptation of neoplastic cells to hypoxia-induced stress connected with imperfect vascularity of the tumors. We have shown, for the first time, that up-regulation HSP110 and HYOU1 expression is associated with lymph nodes involvement in CRC. We validated differences in expression of HSP110 on the group of forty patients in all clinical stages by more precise TaqMan technology and Real-Time PCR method. We identified highly significant up-regulation (mean 50x) of HSP110 expression in colorectal tumors compared to adjacent non-tumoral mucosa ($p<0,0001$). We observed also correlation of HSP110 and tumor stage but this association was not significant. At the moment, validation of the rest of identified changes in gene expression is undergoing in our lab by more precise quantification method on the mRNA level and also on protein level by immunohistochemistry. Our preliminary data suggest important role of HSP110 in colorectal cancer pathogenesis. Supported by IGA MZ CR NR/9076 – 4 and project MZ0MOU2005

497 Poster

A dietary phytochemical cocktail impedes prostate cancer growth in vitro and in vivo

J. Singh[1], M. Yao[1], G. Jardine[2], Q. Dong[1]
[1]University of Sydney, Department of Medicine, Sydney NSW, Australia; [2] Dr. Red Nutraceuticals, Mt Nebo, Qeensland, Australia

Background: Phytochemicals have been reported to interfere with specific stages of the carcinogenic process [1]. Some of these phytochemicals like curcumin induce apoptosis and cell cycle arrest in prostate cancer cells [2] while green tea has been shown to inhibit prostate cancer development and distant site metastasis in TRAMP mice [3]. Similarly, resveratrol has also been associated with inhibition of various cancers. Based on the premise that a combination of phytochemicals in their dietary form is likely to be as effective as individual molecules in reducing cancer cell proliferation, we investigated the in vitro and in vivo effects of a dietary cocktail, Blueberry Punch (BBP; Dr Red Nutraceuticals Pty Ltd, Queensland, Australia), that incorporates the above mentioned phytoconstituents, on prostate cancer growth.

Materials and Methods: BBP ingredients include fruit juice concentrate (blueberry, red grapes, raspberry and elderberry), grape seed and skin extract, citrus skin extracts, green tea extract, olive leaf/olive pulp extracts, tarragon, turmeric and ginger. Cell growth and DNA synthesis were assessed by MTS and ^{3}H-thymidine incorporation assay respectively. Protein levels were evaluated using Western blotting and immuno-histochemistry. For in vivo studies, immunodeficient nude Balb/C mice were inoculated with 5 x 10^5 prostate cancer cells (PC3) and treatment commenced when the tumors reached between 150-200mm^3. Tumor volumes and body weights were monitored twice per week.

Results: Prostate cancer cell (PC3, LNCaP) growth showed a dose-dependent reduction compared with untreated cells after 72 hours of exposure to increasing concentrations (0.08% - 5%) of BBP and this reduction in cell growth was due to decreased DNA synthesis. Non-cancer prostate epithelial cells (PrEC) exposed to same concentrations of BBP demonstrated resistance in terms of cell growth reduction. Exposing cancer cells to varying concentrations of mannitol indicated that the observed effects on cancer cell growth were independent of osmolarity. PC3 cells exposed to BBP showed decreased levels of COX-2, phospho-cytosolic phospholipase A2 and Cyclin D1 protein. Tumor bearing mice (n = 8/group) were administered BBP (10%) in drinking water for two weeks. At two weeks of treatment the tumor size showed a significant decrease ($p = 0.004$, by two-way ANOVA with repeated measures) compared with mice (n = 8) that were administered regular tap water. Immunostaining for Cyclin D1 indicated decreased protein in xenografts from mice administered BBP.

Conclusions: BBP shows suppressive effects on prostate cancer cell growth both in vitro and in vivo. Further studies to determine the mechanistic pathways involved in the inhibition of cancer cell growth are in progress.

1. Surh YJ (2003) Nat Rev Cancer, 3; 768-780
2. Khor et al (2006) Cancer Res, 66; 613-21
3. Gupta (2001) PNAS, 98; 10350-10355

498 Poster

Characterization of dose-dependent metabolic changes in melanoma cells after irradiation in vitro and in vivo

B. Mosch[1], K. Müller[1], J. Pietzsch[1]
[1]Forschungszentrum Dresden-Rossendorf e.V. Institute of Radiopharmacy, Radiopharmaceutical Biology, Dresden, Germany

Background: Although irradiation is a powerful tool for the therapy of solid tumors, single cells often elude this treatment and constitute a basis for recurrence of the primary tumor and formation of metastases. This rises the question if irradiation-dependent metabolic changes could be responsible for a predisposition of certain cells to show enhanced survival and migratory activity. The aim of our study was to investigate metabolic properties of irradiated melanoma cells and thus to develop and validate appropriate in vitro and in vivo models to characterize new radio-pharmaceuticals for diagnosis and therapy of metastases and solid tumors.

Materials and methods: We applied different single-dose X-ray irradiation (1, 2, 5, 7, 10, and 20 Gy) to murine B16-F10 melanoma cells. At particular times we analyzed cell viability, growth properties, clonogenic regrowth capability, cellular proliferation, and expression of cell cycle markers. Furthermore, we analyzed the cellular uptake of the radiotracers 2-[^{18}F]Fluor-2-desoxy-D-glucose and 3-O-Methyl-[^{18}F]fluor-L-DOPA, providing information about the glucose and amino acid metabolism before and after irradiation. Additionally, we performed in vivo studies in a syngeneic mouse model to analyze the capability of untreated and irradiated cells to form lung metastases.

Results: In a dose-dependent manner we detected a decrease in the viability, growth properties and tracer uptake of the melanoma cells. These findings appeared particularly in the period 3 to 6 days after irradiation. In contrast, already one day after irradiation cell cycle analyses showed an increase in the number of G2/M phase cells and the expression of G2-phase markers in irradiated compared to untreated cells. Further we demonstrated an influence of irradiation according to the ability to form lung metastases in the mouse.

Conclusions: Our results indicate that the combination of different in vitro and in vivo approaches is useful for a detailed characterization of metabolic changes in melanoma cells after irradiation. Additionally, the presented approach gives information about dose-dependent effects. These models enable us to characterize new radiotracers and furthermore, to investigate metabolic effects of applied radiopharmaceuticals in combination with experimental radiation therapy.

499 Poster

Molecular changes during transdifferentiation of androgen-dependent prostate cancer cells involve overexpression of mithocondrial superoxide dismutase

I. Quiros[1], D. Hevia[1], R.M. Sainz[1], J.C. Mayo[1]
[1]Instituto Oncologico del Principado de Asturias IUOPA, Morfología y Biología Celular, Oviedo, Spain

Prostate cancer therapies have proved to be very ineffective in androgen-independent tumor status. During the last decade some groups have pointed out the possibility that NE cells could play a key role in the transition to androgen independence and in highly resistance to conventional treatment. Among other factors this cellular resistance can also be related with an overexpression of antioxidant cellular defences. Based on this hypothesis we have tried to establish a connection between superoxide dismutase activity, which could explain the high apoptosis resistance shown by NE cells, and the transdifferentiation of androgen-dependent LNCaP cells to NE-like cells. NE phenotype was induced by mean of the endogenous antioxidant melatonin, di-butiryl cyclic adenosine-mono-